AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|
13.3 C
New York
Thursday, November 12, 2026

Tag: PHA BIO MTC HEA

newsFORsourcecompanycontentinformationreleases1IT

Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF...

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society...

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across...

Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids

Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and adipose tissue—and localized routes across ocular, joint, and bladder...

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its...

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPHA BIO MTC HEA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers